Foundayo
4 articles on Foundayo, written by Shotlee and medically reviewed for clinical accuracy.
Foundayo: Lilly's New Oral GLP-1 Pill for Weight Loss Now in US
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
5 min read
Amazon Adds Same-Day Delivery for GLP-1 Drug Foundayo
Amazon is revolutionizing access to GLP-1 weight-loss drugs by launching same-day delivery for Foundayo through Amazon Pharmacy in nearly 3,000 cities. Patients can now order with a valid prescription, check real-time availability, and get medication home-delivered faster than traditional options. This move cuts treatment barriers from prescription to doorstep.
4 min read
Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
5 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read